CY
CYTK
CYTK What CYTOKINETICS promised, and what happened
Guidance
What management said, and what became of it
15 of 23 judged targets kept · 10 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Completion of enrollment in the adolescent cohort of CEDAR-HCM | Complete enrollment in the adolescent cohort of CEDAR-HCM in Q4 2026 | Dec 2025 | during the quarter, we completed enrollment in the adolescent cohort ahead of prior expectations | Achieved |
| Completion of patient enrollment in COMET-HF | Complete enrollment in COMET-HF in 2026 | Dec 2024 | not providing specific guidance on when we think it will complete enrollment, but it will be into the beginning of 2027 for sure | Missed |
| Full-year 2026 GAAP combined R&D and SG&A expense | $830 million to $870 million | Dec 2025 | We are updating full year 2026 GAAP combined R&D and SG&A expense to a range of $860 million to $890 million from the previous range of $830 million to $870 million. | Revised Down |
The full ledger
Open CYTOKINETICS’s full ledger
A free account opens 5 company ledgers a month. All 33 tracked commitments, with each call’s wording and source.
The rest of the ledger
Pro opens all 33 tracked commitments for CYTOKINETICS
Above is what the last two calls moved. Pro adds every quarter's revision, the source quote behind each one, and the topics management has stopped answering.